Reviving EU Pharma: Draghi’s Blueprint for Survival
In European boardrooms, where modesty often masquerades as pragmatism, it is rare for a leader to sound the alarm with
The problem with POS
The Problem with Probability of Success (POS) in Biotech and Pharma
Probability of Success (POS) is a widely used metric
Progression-Free Survival: The Metric That Divides Science, Business, and Payors
Few metrics in modern oncology trials command the prominence of progression-free survival (PFS). As a measure of time until disease
Europe’s Competitiveness Compass: Will Pension Funds Finally Back Innovation?
Brussels has a new plan. The Competitiveness Compass, the European Commission’s latest attempt to reinvigorate the EU economy, comes
Licensing Deals: David’s Slingshot, Goliath’s Throne
For decades, licensing deals have been the biotech-pharma relationship’s bread and butter—a veritable match made in heaven, or
Europe’s Biotech Grants: A Lifeline or a Leash?
Europe’s biotech sector has always been fond of government grants. Programs like Horizon Europe, with its eye-watering €95.5
To Quad or Not to Squad?
Have you noticed something peculiar creeping into the corporate world? A proliferation of titles that sound less like professional roles
Serial Founders: The Myth, the Bias, and the LinkedIn Title
Ah, the serial founder. That darling of venture capital, the endlessly inventive entrepreneur who builds company after company, racking up
The problem with WACC
The Weighted Average Cost of Capital (WACC) is a foundational metric in corporate finance, designed to evaluate the opportunity cost
The problem with CAPM
The Capital Asset Pricing Model (CAPM) is one of the most widely used and taught frameworks in finance, offering a
